Soft Tissue Sarcoma Global Market Report 2024

The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $2.87 billion in 2023 to $3.13 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth observed in the historical period can be attributed to factors such as limited treatment options for soft tissue sarcoma, an evolving understanding of sarcoma biology, increased funding for cancer research, the rising prevalence of soft tissue sarcoma, and the expansion of healthcare infrastructure.

The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $4.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to the development of targeted therapies for soft tissue sarcoma, an increasing focus on personalized medicine, the expansion of clinical trials for sarcoma treatments, and growing awareness and early detection initiatives. Key trends expected in the forecast period include the integration of immunotherapy in soft tissue sarcoma treatment, the development of combination therapies, an emphasis on patient-centric care models, a rise in the use of liquid biopsies, and advances in sarcoma genomics.

The anticipated increase in cancer incidence is poised to drive the future growth of the soft tissue sarcoma market. Cancer, a diverse group of illnesses, manifests in organs or tissues when abnormal cell proliferation exceeds normal boundaries, potentially spreading to other organs or neighboring body parts. The upsurge in cancer incidence intensifies the demand for diagnostic procedures, therapeutic approaches, and supportive care options tailored to the unique needs of patients with various cancer types or sarcoma. This surge significantly contributes to the expansion of the soft tissue sarcoma market. For example, the American Cancer Society reported 1.8 million new cancer cases diagnosed in 2020. Additionally, data from September 2020 by the National Cancer Institute revealed 1,806,590 new cancer cases, indicating a 43% diagnosis rate in men in the United States in 2020, up from 1,752,735 in 2019. Hence, the rise in cancer incidence is a driving force behind the growth of the soft tissue sarcoma market.

The escalating healthcare expenditure is expected to propel the advancement of the soft tissue sarcoma market. Healthcare encompasses the organized provision of medical services, treatments, preventive care, and health issue management for individuals or communities. Higher healthcare expenditures can lead to increased funding for medical research, including cancer research. This, in turn, may result in advancements in understanding soft tissue sarcoma, the discovery of novel treatment modalities, and overall improvement in patient outcomes. For instance, India's public expenditure on healthcare stood at 2.1% of GDP in 2021–22, as per the Economic Survey of 2022. Additionally, a survey by Willis Towers Watson revealed a global increase in healthcare benefit costs from 8.2% in 2021 to 8.8% in 2022, expected to rise further to a global average of 10% in 2023. Therefore, the heightened healthcare expenditure is set to drive the growth of the soft tissue sarcoma market.

Product innovation has emerged as a prominent trend gaining traction in the soft tissue sarcoma market. Major companies within this market are focusing on developing innovative products to fortify their market position. For instance, in November 2023, Mercy, a not-for-profit Catholic health care organization in the US, introduced The Chen Chemotherapy Model - an AI-driven texting program. This program utilizes a smart texting platform to proactively prevent chemotherapy-related hospitalizations by sending daily messages to chemotherapy patients, allowing them to report symptoms and enabling timely intervention. This showcases Mercy's commitment to leveraging technology for enhanced patient care in the chemotherapy field.

Research projects, such as the Leiomyosarcoma Project (LMS), are a focal point for major companies operating in the soft tissue sarcoma market to sustain their market standing. The Leiomyosarcoma Project (LMS) aims to advance scientific understanding and discovery related to leiomyosarcoma - a rare and aggressive cancer originating in smooth muscle cells. Count Me In, a non-profit cancer research initiative, launched the LMS project in September 2022, inviting individuals with this rare cancer to actively participate in research. The initiative seeks to accelerate scientific discovery by engaging patients and encouraging them to share their health data, fostering a collaborative and data-driven approach to improve outcomes for those with rare cancers.

In August 2022, Ipsen SA, a French biopharmaceutical company, acquired Epizyme Inc. for an undisclosed amount. This acquisition grants Ipsen SA access to Epizyme's lead drug, Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2 inhibitor, and the oral SETD2 inhibitor, EZM0414. Epizyme Inc., a US-based biopharmaceutical company, specializes in developing drugs for treating soft tissue sarcoma.

Major companies operating in the soft tissue sarcoma market report are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

North America was the largest region in the soft tissue sarcoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the soft tissue sarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main treatment modalities for soft tissue sarcoma include targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and other supportive approaches. Targeted therapy is a treatment method that specifically focuses on the genes, proteins, or tissue environment supporting the growth and survival of cancer cells. It aims to hinder cancer cell proliferation, division, and the creation of new cells. These treatments can be administered through various routes, including oral and parenteral methods. Soft tissue sarcoma treatments are utilized across different healthcare settings, such as hospitals, homecare, specialty centers, and others.

The soft tissue sarcoma market research report is one of a series of new reports that provides soft tissue sarcoma market statistics, including soft tissue sarcoma industry global market size, regional shares, competitors with a soft tissue sarcoma market share, detailed soft tissue sarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue sarcoma industry. This soft tissue sarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The soft tissue sarcoma includes revenues earned by entities by immunotherapy, hormone therapy, photodynamic therapy, and stem cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.